Immune Response
Patent approval, 2017, All patent inquiries should be directed to James Passé at Passé Intellectual Properties, LLC. 919-356-8199 or 1717 Brassfield Rd, Raleigh, NC 27614
Seeking Balance
Gut Health — Our inner economy is reliant on a variety of microbiota, the importance of which is well understood here at Bioavivus. Of course, each microbe does its respective job admirably, though some may run rampant (when conditions are favorable) growing in number to such a degree as to destabilize the efficacy of the biosystem. We call this imbalance dysbiosis. Working correctly these microorganisms will be in a state of symbiosis. When you feel out-of-sync or ill-at-ease, this dis-ease is your warning of impending illness and must be addressed before becoming untenable, requiring a doctor's care or even hospitalization. Our highly qualified team is focused on developing solutions that do not upset this vital balance, while keeping in mind that frequently, less is more. Since the mid-1940’s, antibiotics have served the test of time in reducing both morbidity and mortality rates from pathogenic infections. Now, these little, but virulent, bacteria cells have caught on to the way antibiotics communicate with bacteria, and they create a constant “busy signal” that prevents the bacteria from listening to the antibiotics’ call for wellness and prevents them from penetrating and delivering its medicine to the appropriate location in the bacteria, resulting in inflammation, pain, and infection. This phenomena has resulted in a pandemic wherein current-day antibiotics no longer respond in the expected manner. From the world of bacteriology, we’ve recently learned that bacteria form what are called ‘quorums.’ A quorum is a deliberative group of germs that work in unison to plan their pattern of attack, creating infections in or on our bodies. Physicians call this communication event ‘quorum sensing’ (QS). The Bioavivus Strategy - Instead of developing new antibiotics from scratch, and to avoid extremely risky costs** of such a challenge, Bioavivus Pharma has re-focused its research from attempting to create new antibiotics, to a strategy of exploiting newly discovered communication pathways that obliterate these “busy bacteria signals.” In other words, we’ve discovered and patented the first drug to inhibit quorum sensing. This opens up a new ultra-fast “expressway” to transport our drug to its home target, resulting in recovery and healing from infectious diseases. Our initial destination is to inhibit one of the most pathogenic bacteria (Pseudomonas aeruginosa) from traveling on our expressway. **The Tufts Center for the study of drug development released an estimate of $2.6 billion to bring a new antibiotic to market.
We are a biotech company focused on nanofication and repurposing of existing, tested and approved chemical compounds.


Charles W. Vaughn, President/CEO, former C-Level Executive, Pfizer, Novariti Fellow, American Society of Angiology.


Richard K. Bogan, M.D., Exec. Sr. Vice-President and Chief Medical Officer, Fellow of The American Academy of Sleep, Board Certified Pulmonology.


Peter Kowey, M.D., Cardiology, Electrophysiology, Jefferson Medical College, Thomas Jefferson University.


Harry D. Oberkefell, former President Parke-Davis.


Michael E. George, former President DuPont-Merck.


Barry Buzogany, Esq., former C-Level Pharmaceuticals and Bio-Tech.


Dr. David J. Durgan, Assistant Professor, Anesthesiology, Baylor College of Medicine, Project Leader National Institute of Health, Human Microbiome Project.


Thank you for your interest in BioAvivus. Please use this form if you have any questions about what we do and we will get back to you very soon.